DiaMonTech AG

  • WKN: A255G4
  • ISIN: DE000A255G44
  • Land: Deutschland

Nachricht vom 19.11.2019 | 11:12

DiaMonTech: First-time product presentation of the 'D-Base' at the world-wide largest medical technology trade fair COMPAMED/MEDICA 2019


DGAP-Media / 19.11.2019 / 11:12

DiaMonTech: First-time product presentation of the 'D-Base' at the world-wide largest medical technology trade fair COMPAMED/MEDICA 2019
 

Berlin, 19 November 2019 - The DiaMonTech product 'D-Base', a device for the non-invasive blood glucose measurement, is exhibited for the first time at a trade fair. The partner company seleon GmbH, a leading international medical technology service provider, will present the measuring device at its stand at the COMPAMED/MEDICA 2019 medical technology trade fair. Visitors will have the opportunity to test the device in hall 8b at stand G05 and can thus determine their blood glucose level precisely and completely painlessly within seconds.

"We are pleased to be able to exhibit the 'D-Base' at our stand. It is one of the major innovations at this year's COMPAMED/MEDICA 2019. As a partner of DiaMonTech, we have contributed to the development of this great technology", says Harald Genger, managing director of seleon GmbH. "We perceive this technology as a milestone for millions of diabetics in Germany. Visitors to our stand can familiarise themselves with the new measuring technology."

The 'D-Base' allows non-invasive blood glucose measurement using a laser-based technology and is optimized for use in professional environments (e.g. diabetes centers). The measuring instrument received the CE-certification in March this year. The handling is simple: the user places his finger on a sensor field for a few seconds and the blood glucose level is shown on a display. The blood sugar can thus be measured precisely and painlessly without a drop of blood. The measurement can be made as often as desired without consumables (test strips). The need to prick several times a day is therefore completely omitted.

"The successful use of the 'D-Base' in practice is based on more than 20 years of intensive research and development work. We are working hard to make this technology available to as many diabetes patients as possible as quickly as possible, thereby making their lives easier. For this purpose, we are developing the smaller 'D-Pocket' in the size of a smartphone. We intend to launch this product on the market at the end of next year. It could thus be a constant 'companion' for diabetes patients", says Thorsten Lubinski, Co-founder and CEO of DiaMonTech AG.

About DiaMonTech
DiaMonTech AG is a medical technology company that specializes in the development, design and sale of products for medical diagnostics. The patented photothermal detection technology based on infrared lasers enables the precise measurement of relevant blood parameters. The first application is the non-invasive blood glucose measurement, which enables an accurate and fast measurement without pain.

More information about DiaMonTech can be found at www.DiaMonTech.de/home.

About seleon
seleon GmbH has been developing and producing complex equipment for customers in the medical technology field since 1998, growing into a leading medical technology service provider. We develop individual solutions in partnership with our customers around the world, quickly leading to success. With our team of experienced physicists, engineers, computer scientists, process engineers and consultants, every one of our projects reaffirms our ambition to find innovative solutions and help our customers succeed in the market.

More information about seleon can be found at https://www.seleon.de.

Press Contact
Alexander Neblung
Kirchhoff Consult AG
Phone +49 40 60 91 86 70
E-Mail DiaMonTech@kirchhoff.de



End of Media Release


Issuer: DiaMonTech AG
Key word(s): Research/Technology

19.11.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

IPO im Fokus

MIT SICHERHEIT AUFS PARKETT. UNSER BÖRSENGANG ZUR WACHSTUMSBESCHLEUNIGUNG

ISIN: DE000A3CM708
Grundkapital (vor IPO): 3.120.000 EUR
Angebotene Aktien: bis zu 690.000 Aktien
Zeichnungsfrist: 11.10.2021 bis voraus. 25.10.2021
Bookbuildingspanne: 3,30 bis 3,60 Euro
Börse: Börse Düsseldorf

Rechtlich maßgeblicher Wertpapierprospekt auf sdm-se.de

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC im Fokus

Börsengang sdm SE: Attraktives Investment

Der Sicherheitsdienstleister sdm SE führt derzeit einen Börsengang am Primärmarkt der Börse Düsseldorf durch. Die Mittel des Börsengangs sollen die Wachstumsstrategie finanzieren und die Ertragskraft deutlich steigern. Im Rahmen unseres DCF-Bewertungsmodells haben wir einen fairen Unternehmenswert (Post Money) zum Ende des Geschäftsjahres 2022 in Höhe von 15,23 Mio. € bzw. 4,09 € je sdm-Aktie ermittelt. Unter einem Preis von 3,50 € pro Aktie sehen wir sdm als ein attraktives Investment und stufen die Aktie mit dem Rating „Kaufen“ ein.

News im Fokus

Continental passt Ausblick für das Geschäftsjahr 2021 an und veröffentlicht vorläufige Kennzahlen für das dritte Quartal 2021

22. Oktober 2021, 14:11

Aktueller Webcast

TRATON SE

Pressekonferenz – Zwischenmitteilung 9M 2021 - Webcast

28. Oktober 2021

Aktuelle Research-Studie

Aves One AG

Original-Research: Aves One AG (von GBC AG): Halten

21. Oktober 2021